PMID- 26732230
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20181202
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 9
IP  - 3
DP  - 2016
TI  - Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: 
      rationale and evidences.
PG  - 409-18
LID - 10.1586/17512433.2016.1131121 [doi]
AB  - Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are recently approved class 
      of anti-hyperglycaemic agents for the treatment of type 2 diabetes mellitus 
      (T2DM). SGLT-2I inhibits renal glucose reabsorption, thereby ensuing urinary 
      glucose excretion in a dose-dependent manner. This caloric loss and osmotic 
      diuresis, secondary to increased urinary glucose excretion, has a unique 
      potential to counter insulin induced weight gain and fluid retention, with little 
      potential of hypoglycemic exacerbation. Also, as these agents act independently 
      of insulin secretion or action, they are effective even in long-standing diabetes 
      with depleted beta-cell reserve. Improvement in insulin sensitivity, as observed 
      with SGLT-2I can also facilitate insulin action. Furthermore, significant 
      reduction in total daily insulin dosage and reduction of body weight as observed 
      during combination therapy renders SGLT-2I, a near-ideal partner to insulin. This 
      review aims to evaluate the safety and efficacy of currently used SGLT-2I as an 
      add-on to insulin therapy in the treatment of T2DM.
FAU - Singh, Awadhesh Kumar
AU  - Singh AK
AD  - a G.D Hospital & Diabetes Institute , Kolkata , India.
FAU - Singh, Ritu
AU  - Singh R
AD  - a G.D Hospital & Diabetes Institute , Kolkata , India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160105
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Insulin/administration & dosage/metabolism/therapeutic use
MH  - Insulin Resistance
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Sodium glucose co-transporter-2 inhibitors
OT  - genito-urinary infection
OT  - hypoglycemia
OT  - insulin
OT  - type 2 diabetes
EDAT- 2016/01/07 06:00
MHDA- 2016/10/08 06:00
CRDT- 2016/01/07 06:00
PHST- 2016/01/07 06:00 [entrez]
PHST- 2016/01/07 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
AID - 10.1586/17512433.2016.1131121 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2016;9(3):409-18. doi: 10.1586/17512433.2016.1131121. 
      Epub 2016 Jan 5.